Skip to content
DraconiticResearch
Search Sources API
203,952 studies31 sourcesUpdated 42 min ago
Peer-reviewedCC BYLife (Basel, Switzerland)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis (MASLD/MASH) and Cardiovascular Risk: Emerging Therapeutic Strategies at the Interface of Liver and Cardiometabolic Disease

Read full textPDFCite

Related

  1. Multiomics, multi-species profiling, and animal validation identify mitoxyperilysis as a conserved therapeutic target in metabolic dysfunction-associated steatohepatitis.
    Hanjie Liu, Cong Qi, Ruixia Lu +6
    Biology directPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMCDOAJ
  2. Beyond hepatoprotection: a meta-analysis quantifying the cardiovascular benefit of antidiabetic drugs in patients with metabolic dysfunction-associated steatohepatitis
    Najeeb Ullah, Yasen Mijiti, Guoli Du
    Frontiers in EndocrinologyPeer-reviewedCC BY 4.0Endocrinology & metabolismCrossref
  3. Estimated glucose disposal rate outperforms other insulin resistance surrogate indices in predicting cardiometabolic disease and major adverse cardiovascular events in metabolic dysfunction-associated steatotic liver disease: insights from UK Biobank
    Zhikang Wu, Yiqing Zhang, Xin Tan +7
    Cardiovascular DiabetologyPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
  4. Xiaochaihutang Extract Ameliorates Metabolic Dysfunction-Associated Steatohepatitis in Mice and Modulates the Gut–Liver Axis
    Antioxidants (Basel, Switzerland)Peer-reviewedCC BYFull textEurope PMC
  5. Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) : A systematic review and meta-analysis
    Mohammed Alfawaz, Dareen Bajamaan, Lama Alghamdi +7
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{anon2026metabolic,
  title = {{Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis (MASLD/MASH) and Cardiovascular Risk: Emerging Therapeutic Strategies at the Interface of Liver and Cardiometabolic Disease}},
  journal = {Life (Basel, Switzerland)},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13705867},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis (MASLD/MASH) and Cardiovascular Risk: Emerging Therapeutic Strategies at the Interface of Liver and Cardiometabolic Disease
PY  - 2026
DA  - 2026/10/01
JO  - Life (Basel, Switzerland)
UR  - https://europepmc.org/article/PMC/PMC13705867
SN  - 2075-1729
ER  -